Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07344948 · ClinicalTrials.gov registry record · Early Phase 1
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
A Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis, sponsored by Neurosterix.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT07344948: Recruiting Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis, sponsored by Neurosterix.
NCT07344948 is a Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis that is actively recruiting participants, run by Neurosterix. The registered enrollment target is 73 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07344948, a Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis, is actively recruiting participants, sponsored by Neurosterix.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Primary Outcome
Safety and tolerability will be assessed by the incidence and severity of treatment-emergent adverse events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NTX-253
Study Locations (1)
California
- Collaborative Neuroscience Research, LLC - CenExel - Los Alamitos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-05 |
| Phase | Early Phase 1 |
What NCT07344948 shows while recruiting
NCT07344948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher).
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07344948 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07344948 about?
NCT07344948 is a clinical study titled "Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia". This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
What is the current status of trial NCT07344948?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 73 participants. The study started on 2025-10-03. Estimated completion is 2026-05.
What conditions does trial NCT07344948 study?
This clinical trial studies the following conditions: Healthy Participants, Schizophrenia Diagnosis.
What interventions are being tested in trial NCT07344948?
The interventions under investigation include: Placebo (DRUG), NTX-253 (DRUG).
Who is sponsoring clinical trial NCT07344948?
This trial is sponsored by Neurosterix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07344948 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07344948's enrollment target sits among peer trials
73 33rd of 119 higher than 86 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
Researching Economical Adjuvants to Cancer Therapy
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
Washington University WU 409: Immune Responses to Rabies Vaccine.
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI